Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-28
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
News release - English.pdf
Results 2026-05-12
Interim financial statements/report – English.pdf
Results 2026-05-12
Interim MD&A - English.pdf
Results 2026-05-06
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
News release - English.pdf
Results 2026-05-05
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
News release - English.pdf
News 2026-04-22
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
News release - English.pdf
Results 2026-04-21
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
News release - English.pdf
Ownership 2026-03-18
2 insiders · +$38k net
Insider trading – 2026-03-18
2 insiders · +$38k net
Results 2026-03-17
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
News release - English.pdf
Results 2026-03-13
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
News release - English.pdf
Results 2026-03-13 Financials
Annual MD&A - English.pdf
Results 2026-03-13 Financials
Audited annual financial statements – English.pdf
Results 2026-03-13 Financials
Annual information form - English.pdf
Transactions 2026-02-23 Financing
Eupraxia Pharmaceuticals Inc. Announces Closing of Public Offering of Common Shares and Pre-Funded Warrants for Gross Proceeds of Approximately US$63.2 Million
Material change report - English.pdf
Ownership 2026-02-21
Freedman, Joseph Stuart bought +$2.3M
Insider trading – 2026-02-21
1 insider · +$2.3M net
Transactions 2026-02-20 Financing
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
News release - English.pdf
News 2026-02-19
Underwriting or agency agreements (or amendment thereto).pdf
News 2026-02-19
Consent letter of issuer's legal counsel.pdf
Transactions 2026-02-19
Prospectus (non pricing) supplement (other than ATM) – English.pdf
Transactions 2026-02-19 Financing
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
News release - English.pdf
Transactions 2026-02-18
Draft shelf prospectus supplement – English.pdf
Transactions 2026-02-18 Financing
Eupraxia Pharmaceuticals Announces Proposed Public Offering
News release - English.pdf
Results 2026-01-08
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
News release - English.pdf
Ownership 2025-11-26
Brennan, Paul Anthony bought +$144k
Insider trading – 2025-11-26
1 insider · +$144k net
News 2025-11-13
News release - English.pdf
Results 2025-11-04 Financials
Interim MD&A - English.pdf
Results 2025-11-04 Financials
Interim financial statements/report – English.pdf
News 2025-11-04
News release - English.pdf
Ownership 2025-09-30
Glickman, Richard bought +$27k
Insider trading – 2025-09-30
1 insider · +$27k net
News 2025-09-29
News release - English.pdf
News 2025-09-25
Material change report - English.pdf
News 2025-09-24
News release - English.pdf
Ownership 2025-09-24
4 insiders · +$3.4M net
Insider trading – 2025-09-24
4 insiders · +$3.4M net
News 2025-09-23
Underwriting or agency agreements (or amendment thereto).pdf
News 2025-09-23
Consent letter of issuer's legal counsel.pdf
News 2025-09-23
Auditors' consent letter.pdf
News 2025-09-23
Consent letter of underwriters' legal counsel.pdf
Transactions 2025-09-23
Prospectus (non pricing) supplement (other than ATM) – English.pdf
News 2025-09-23
News release - English.pdf
News 2025-09-22
News release - English.pdf
Transactions 2025-09-22
Draft shelf prospectus supplement – English.pdf
News 2025-09-02
News release - English.pdf
Results 2025-08-12 Financials
Interim financial statements/report – English.pdf
Results 2025-08-12 Financials
Interim MD&A - English.pdf
News 2025-08-12
News release - English.pdf
News 2025-07-22
News release - English.pdf
News 2025-07-08
News release - English.pdf
Ownership 2025-06-19
Freedman, Joseph Stuart bought +$183k
Insider trading – 2025-06-19
1 insider · +$183k net
Ownership 2025-06-09
Freedman, Joseph Stuart sold +$100k
Insider trading – 2025-06-09
1 insider · −$100k net
News 2025-06-02
News release - English.pdf
Ownership 2024-09-11
Wilmink, Michael bought +$5k
Insider trading – 2024-09-11
1 insider · +$5k net
Ownership 2024-07-01
Montalbano, John bought +$52k
Insider trading – 2024-07-01
1 insider · +$52k net
Ownership 2024-06-17
Wilmink, Michael bought +$3k
Insider trading – 2024-06-17
1 insider · +$3k net
Ownership 2024-06-12
Wilmink, Michael bought +$2k
Insider trading – 2024-06-12
1 insider · +$2k net
Ownership 2024-06-09
Wilmink, Michael bought +$3k
Insider trading – 2024-06-09
1 insider · +$3k net